Trials / Unknown
UnknownNCT02999841
Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients
Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Peking University · Academic / Other
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Focusing on newly diagnosed type 2 diabetes participants with overweight and obesity (24kg/m2 ≤ body mass index ≤ 30kg/m2). 50 participants per arm (acarbose \& lifestyle combination / vildagliptin \& lifestyle combination), using abdominal computed tomography scans and other methods to evaluate the effects of acarbose and vildagliptin on visceral fat distribution in overweight and obesity patients with newly diagnosed type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Acarbose | 1-2 week: 50mg tid; 3-24 week: 100mg tid. |
| DRUG | Vildagliptin | 1-24 week: 50mg bid |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2017-12-01
- Completion
- 2018-01-01
- First posted
- 2016-12-21
- Last updated
- 2016-12-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02999841. Inclusion in this directory is not an endorsement.